

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/423,259	03/02/2000	CATHERINE HANNI	97- MA- CNR-VI	6537	
466	7590 12/21/2001				
	NG & THOMPSON Examiner		INER		
745 SOUTH 2 ARLINGTON	23RD STREET 2ND FL N, VA 22202	OOR	EINSMANN, JUL	LIET CAROLINE	
			ART UNIT	PAPER NUMBER	
			1/22		

DATE MAILED: 12/21/2001

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
		09/423,259	HANNI ET AL.			
Office Action Summary		Examiner	Art Unit			
		Juliet C Einsmann	1655			
	- The MAILING DATE of this communication app		neet with the correspondence address			
Period for	r Reply					
THE N - Extension after S - If the s - If NO - Failur	DRTENED STATUTORY PERIOD FOR REPLINATION DATE OF THIS COMMUNICATION. Sions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a replination for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statute apply received by the Office later than three months after the mailined patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however	r, may a reply be timely filed Im of thirty (30) days will be considered timely. (6) MONTHS from the mailing date of this communication. Scome ABANDONED (35 U.S.C. § 133).			
1) 	Responsive to communication(s) filed on 17	October 2001 .				
2a)□		his action is non-fina	ıl.			
3)	Since this application is in condition for allow closed in accordance with the practice under	rance except for forr Ex parte Quayle, 1	nal matters, prosecution as to the merits is 935 C.D. 11, 453 O.G. 213.			
Dispositi	on of Claims					
4)⊠	Claim(s) 17-23 and 25-27 is/are pending in the	ne application.				
	4a) Of the above claim(s) is/are withdra	awn from considerat	ion.			
5)[Claim(s) is/are allowed.					
6)⊠	Claim(s) 17-19,21-23 and 25-27 is/are rejected	ed.				
•	Claim(s) <u>20</u> is/are objected to.					
8)□	Claim(s) are subject to restriction and/	or election requiren	ent.			
Applicat	ion Papers					
	The specification is objected to by the Examin					
10)	The drawing(s) filed on is/are: a)☐ acc	epted or b) objecte	d to by the Examiner.			
	Applicant may not request that any objection to	the drawing(s) be held	in abeyance. See 37 CFR 1.85(a).			
11)[The proposed drawing correction filed on					
	If approved, corrected drawings are required in I		on.			
	The oath or declaration is objected to by the E	=xaminer.				
	under 35 U.S.C. §§ 119 and 120		11 0 0 0 110() (d) (f)			
i	Acknowledgment is made of a claim for forei	ign priority under 35	U.S.C. § 119(a)-(a) or (t).			
a))⊠ All b)□ Some * c)□ None of:					
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority docume					
*	3. Copies of the certified copies of the prapplication from the International I See the attached detailed Office action for a li	Bureau (PCT Rule 1	7.2(a)).			
14)	Acknowledgment is made of a claim for dome	estic priority under 3	5 U.S.C. § 119(e) (to a provisional application).			
]	a) The translation of the foreign language packnowledgment is made of a claim for dome	provisional applicati	on has been received.			
Attachme						
1) No	tice of References Cited (PTO-892) tice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(s	4)	Interview Summary (PTO-413) Paper No(s) Notice of Informal Patent Application (PTO-152) Other:			

Page 2

Application/Control Number: 09/423,259

Art Unit: 1655

DETAILED ACTION

1. This action is written in response applicant's correspondence submitted 10/17/01, paper number 19. Claims 24 has been canceled and claims 19 and 22 have been amended. Claims 17-23 and 25-27 are pending. Applicant's amendments and arguments have been thoroughly reviewed, but are not persuasive for the reasons that follow. Any rejections not reiterated in this action have been withdrawn. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Continued Examination Under 37 CFR 1.114

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/17/01 has been entered.

Claim Objections

3. Claim 20 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections - 35 USC § 112

4. Claims 22 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1655

Claim 22 is indefinite over the recitation "each primer being selected from" because with this recitation it is not clear if the primer pairs can be comprised of any two primers that are listed next, or if the claimed primer pairs are the specific groupings recited in the claims.

Amendment of the claim to read "each primer pair being selected from" will obviate this rejection.

Claim Rejections - 35 USC § 103

5. Claims 17-19, 21-23 and 25-27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Loftus *et al.* (PNAS USA, Vol. 91, pp. 2757-2761, March 1994) in view of Fei *et al.* (Animal Science and Technology (1996) Vol. 67, No. 10, pp. 900-905).

Loftus *et al.* teach the sequences of the D loops of the mtDNA from a number of cattle breeds. These sequences are fully disclosed in GenBank accession numbers L27712-27737.

Instant SEQ ID NO: 2 consists of the complement of nucleotides 685-699 of the sequence disclosed in GenBank Accession number L27725 (see attached GenBank record). Instant SEQ ID NO: 5 consists of nucleotides 230-244 of the sequence disclosed in GenBank Accession number L27725.

Furthermore, the sequence taught by Loftus *et al.* and fully disclosed in GenBank accession number L27725 also comprises instant SEQ ID NO: 9-14. Instant SEQ ID NO: 9 consists of nucleotides 19-43, instant SEQ ID NO: 10 consists of the complement of nucleotides 158-177, instant SEQ ID NO: 11 consists of the complement of nucleotides 358-377, instant SEQ ID NO: 12 consists of nucleotides 441-60, instant SEQ ID NO: 13 consists of nucleotides 715-734, and instant SEQ ID NO: 14 consists of the complement of nucleotides 854-873.

Art Unit: 1655

Instant SEQ ID NO: 8 consists of nucleotides 225-705 of the sequence disclosed in GenBank Accession number L27725. Therefore, this sequence taught by Loftus *et al.* also comprises instant SEQ ID NO: 7 (nucleotides 310-336) and 19 (nucleotides 423-447), which are merely segments of SEQ ID NO: 8.

Instant SEQ ID NO: 15 consists of nucleotides 15824-15981 of the sequence disclosed in GenBank Accession number L27725.

Instant SEQ ID NO: 16 consists of nucleotides 225-337 of the sequence disclosed in GenBank Accession number L27725.

Instant SEQ ID NO: 17 consists of nucleotides 441-705 of the sequence disclosed in GenBank Accession number L27725.

Instant SEQ ID NO: 18 consists of nucleotides 745-902 of the sequence disclosed in GenBank Accession number L27712 (see attached GenBank record).

Loftus et al. do not teach nucleic acids which consist of the instantly claimed nucleic acids, nor do they teach primer pairs which comprise oligonucleotides that consist of the instantly disclosed sequences.

Fei et al. teach methods for specific identification of meat from cattle using the PCR with primers designed to amplify portions of the mitochondrial D-loop DNA sequence (p. 900-905). Primer BF taught by Fei et al. consists of nucleotides 397-416 of the sequence taught by Loftus et al. The primer taught by Fei et al. is considered to be a functional homologue of all of the primers and probes of the instantly claimed invention, since the primer disclosed by Fei et al. possesses the same function as those of the instant invention, namely to amplify and/or detect portions of the D loop mtDNA from cattle.

Art Unit: 1655

In light of the sequences taught by Loftus *et al.* and the teaching by Fei *et al.* that beef samples can be specifically identified by PCR amplification of the D-loop of mitochondrial DNA, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have selected any primers from the sequences taught by Loftus *et al.* in order to have provided functional homologues of the primers taught by Fei *et al.* The selection of different primer pairs from the sequences taught by Loftus *et al.* would have provided the ordinary practitioner with additional mechanisms for the specific amplification and detection of D-loop mitochondrial DNA from beef products in meat samples. The ordinary practitioner would have had a more than reasonable expectation of success since Fei *et al.* teach that amplification with primers specific for the D-loop mtDNA of cattle results in the ability to detect small amounts of beef in a mixed meat sample, for example 0.1% of beef in pork.

Response to Remarks

Applicant's response noted that unexpected results presented in the form of a declaration may be helpful to overcome this obviousness type rejection, and Applicant indicated that such a declaration would be submitted as a supplement to the response filed 10/17/01. As of the time of the writing of this office action, no such response has been filed. Applicant is reminded that with regard to unexpected results, arguments of counsel are not found to be persuasive in the absence of a factual showing. MPEP 716.01(c) makes clear that

"The arguments of counsel cannot take the place of evidence in the record. In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965). Examples of attorney statements which are not evidence and which must be supported by an appropriate affidavit or declaration include statements regarding unexpected results, commercial success, solution of a long - felt need, inoperability of the prior art, invention before the date of the reference, and allegations that the author(s) of the prior art derived the disclosed subject matter from the applicant."

Page 6

Application/Control Number: 09/423,259

Art Unit: 1655

The declaration will be considered when it is received. At this time, however, the rejection over Loftus *et al.* in view of Fei *et al.* is maintained for the reasons of record.

Allowable Subject Matter

- 6. The following is a statement of allowable subject matter as well as reasons for the indication of allowable subject matter: Claims which require the presence of nucleic acids consisting of SEQ ID NO: 3 or consisting of SEQ ID NO: 6 are unobvious over the prior art.

 While the prior art provides longer sequences which comprise SEQ ID NO: 3 and SEQ ID NO: 6, and the prior art provides motivation to design primers for the amplification of bovine mtDNA, this teaching is not sufficient to obviate nucleic acids which consist of SEQ ID NO: 3 or SEQ ID NO: 6. These nucleic acids are considered to be unobvious in light of the unexpected results provided in the specification, wherein these nucleic acids are shown to amplify bovine mtDNA but not that of horse, sheep, pig, duck, chicken or turkey (Figure 1). Further, nucleic acids consisting of SEQ ID NO: 3 and SEQ ID NO: 6 are shown to amplify mtDNA from many different breeds (Figure 2).
- 7. Nucleic acids consisting of SEQ ID NO: 1 and SEQ ID NO: 4 are also unobvious over the prior art of record because these nucleic acids comprise SEQ ID NO: 3 and SEQ ID NO: 6. It is assumed that, although slightly longer, these nucleic acids would function as primers with the same level of specificity as SEQ ID NO: 3 and SEQ ID NO: 6.

Conclusion

Art Unit: 1655

8. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Enclosed with this action, for applicant's convenience is a copy of the English language translation of the entirety of the Fei *et al.* reference.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Juliet C. Einsmann whose telephone number is (703) 306-5824. The examiner can normally be reached on Monday through Thursday, 7:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones can be reached on (703) 308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 and (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Juliet C. Einsmann

Examiner

Art Unit 1655

December 17, 2001

Store Packy Patent Examiner (Cambudge Center 1800